ReviewClinical immunology (Orlando, Fla.)2013
Trials in type 1 diabetes: Antigen-specific therapies.
Review in Clinical immunology (Orlando, Fla.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- Diurnal Variation of Islet Autoantibody Titers in Established Type 1 Diabetes Suggests Restricted-Time Sampling Improves Aab Measurement and Detection.Research square · 2026Article
- Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes.International journal of molecular sciences · 2022Review
- The parasite-derived peptide FhHDM-1 activates the PI3K/Akt pathway to prevent cytokine-induced apoptosis of β-cells.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Auto-antigen and Immunomodulatory Agent-Based Approaches for Antigen-Specific Tolerance in NOD Mice.Current diabetes reports · 2021Review
- Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.Frontiers in immunology · 2021Review
- Neoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets.Frontiers in immunology · 2021Article
- Type 1 diabetes mellitus and its oral tolerance therapy.World journal of diabetes · 2020Review
- Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.Current diabetes reports · 2019Review
- A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes.Journal of autoimmunity · 2019Article
- Article
- Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes.Frontiers in immunology · 2019Review
- Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review.Journal of clinical & cellular immunology · 2019Article
- Metabolically inactive insulin: friend or foe in the prevention of autoimmune diabetes?Diabetologia · 2017Article
- Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice.BMC immunology · 2017Article
- Efficient Presentation of Multiple Endogenous Epitopes to Both CD4Molecular therapy. Methods & clinical development · 2017Article
- Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation.Advanced healthcare materials · 2017Article
- Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes.The pharmacogenomics journal · 2017Article
- Review
- Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes.Stem cells (Dayton, Ohio) · 2016Review
- Immune interventions to preserve β cell function in type 1 diabetes.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Type 1 diabetes (T1D) results from an aberrant immunological response against the insulin-producing beta cells in the islets of the pancreas. The ideal therapy would restore immune balance in a safe and lasting fashion, stopping the process of beta cell decay. The efficacy of immune suppressive agents such as cyclosporin underscores the notion that T1D can in principle be prevented, albeit at an unacceptable long-term safety risk. Immune modulatory drugs such as monoclonal anti-CD3 antibody, on the other hand, have recently had rather disappointing results in phase 3 trials, possibly due to inadequate dosing or choice of inappropriate endpoints. Therefore, it is argued that striking the right balance between safety and efficacy, together with careful trial design, will be paramount in preventing T1D. Here we outline the concept of antigen-specific tolerization as a strategy to safely induce long-term protection against T1D, focusing on available clinical trial data, key knowledge gaps and potential future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.